Clinical Trial

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase Ⅲ, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of narlumosbart (JMT103) in patients with unresectable or surgically difficult giant cell tumor of bone (GCTB). This clinical trial study hypothesizes narlumosbart administration groups are not inferior to active control administration groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-03.
Trial Details
NCT Number NCT05813665
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Giant Cell Tumor of Bone
Enrollment 146 participants
Start Date 2023-04
Primary Completion 2028-06 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2023-04-19